HRP20230273T1 - Cjepivo protiv zika virusa - Google Patents
Cjepivo protiv zika virusa Download PDFInfo
- Publication number
- HRP20230273T1 HRP20230273T1 HRP20230273TT HRP20230273T HRP20230273T1 HR P20230273 T1 HRP20230273 T1 HR P20230273T1 HR P20230273T T HRP20230273T T HR P20230273TT HR P20230273 T HRP20230273 T HR P20230273T HR P20230273 T1 HRP20230273 T1 HR P20230273T1
- Authority
- HR
- Croatia
- Prior art keywords
- zika virus
- virus vaccine
- vaccine according
- sucrose
- zika
- Prior art date
Links
- 229940124743 Zika virus vaccine Drugs 0.000 title claims 17
- 241000907316 Zika virus Species 0.000 claims 17
- 229930006000 Sucrose Natural products 0.000 claims 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 11
- 239000005720 sucrose Substances 0.000 claims 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 9
- 102000007327 Protamines Human genes 0.000 claims 6
- 108010007568 Protamines Proteins 0.000 claims 6
- 229950008679 protamine sulfate Drugs 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 239000012535 impurity Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002458 infectious effect Effects 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000005119 centrifugation Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 1
- 101710145006 Lysis protein Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000020329 Zika virus infectious disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- QUSQOXBLTWQHMU-UHFFFAOYSA-H dialuminum hexahydroxide Chemical group [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3] QUSQOXBLTWQHMU-UHFFFAOYSA-H 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15202585 | 2015-12-23 | ||
| EP16161068 | 2016-03-18 | ||
| EP16176025 | 2016-06-23 | ||
| EP16176049 | 2016-06-23 | ||
| EP16182845 | 2016-08-04 | ||
| EP16828746.4A EP3393510B1 (en) | 2015-12-23 | 2016-12-23 | Zika virus vaccine |
| PCT/EP2016/082664 WO2017109225A1 (en) | 2015-12-23 | 2016-12-23 | Zika virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230273T1 true HRP20230273T1 (hr) | 2023-04-28 |
Family
ID=57821924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230273TT HRP20230273T1 (hr) | 2015-12-23 | 2016-12-23 | Cjepivo protiv zika virusa |
Country Status (19)
| Country | Link |
|---|---|
| US (14) | US10744194B2 (enExample) |
| EP (9) | EP3393507B1 (enExample) |
| JP (1) | JP6949027B2 (enExample) |
| KR (1) | KR20180097558A (enExample) |
| CN (2) | CN108697785B (enExample) |
| AU (1) | AU2016375338B2 (enExample) |
| BR (1) | BR112018012873A2 (enExample) |
| CA (1) | CA3009278A1 (enExample) |
| DK (1) | DK3393510T5 (enExample) |
| ES (4) | ES2973267T3 (enExample) |
| FI (1) | FI3393510T3 (enExample) |
| HR (1) | HRP20230273T1 (enExample) |
| HU (1) | HUE061679T2 (enExample) |
| LT (1) | LT3393510T (enExample) |
| MX (1) | MX2018007627A (enExample) |
| PL (1) | PL3393510T3 (enExample) |
| SG (1) | SG11201805120YA (enExample) |
| SI (1) | SI3393510T1 (enExample) |
| WO (6) | WO2017109228A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9895437B2 (en) | 2012-04-18 | 2018-02-20 | Valneva Austria Gmbh | Aluminum compounds for use in therapeutics and vaccines |
| MY187459A (en) * | 2015-07-16 | 2021-09-23 | Bharat Biotech Int Ltd | Vaccine compositions |
| HUE061679T2 (hu) | 2015-12-23 | 2023-08-28 | Valneva Austria Gmbh | Zika vírus vakcina |
| CA3030154A1 (en) * | 2016-07-08 | 2018-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric dengue/zika viruses live-attenuated zika virus vaccines |
| CR20200082A (es) | 2017-09-21 | 2020-05-17 | Valneva Se | Virus chikungunya inmunogénico |
| US11648304B2 (en) * | 2017-11-03 | 2023-05-16 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| CN107988239B (zh) * | 2017-11-29 | 2021-03-19 | 南方医科大学 | 一种寨卡病毒的重组基因及其制备方法和应用 |
| KR20200090893A (ko) * | 2017-11-30 | 2020-07-29 | 다케다 백신즈 인코포레이티드 | 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들 |
| CN107904215B (zh) * | 2017-12-27 | 2021-07-27 | 华农（肇庆）生物产业技术研究院有限公司 | 一种禽流感病毒的全悬浮培养方法 |
| CN110156880B (zh) * | 2018-02-13 | 2022-12-16 | 吴夙钦 | 兹卡病毒疫苗组合物及其应用 |
| TWI658848B (zh) * | 2018-02-13 | 2019-05-11 | 國立清華大學 | 茲卡病毒疫苗組合物及其應用 |
| CN112088013B (zh) * | 2018-03-26 | 2024-12-06 | 勃林格殷格翰动物保健美国有限公司 | 制备免疫原性组合物的方法 |
| CN108676780B (zh) * | 2018-07-24 | 2021-08-10 | 华中农业大学 | 一种高效分离猪肠道冠状病毒的方法 |
| CN109337876A (zh) * | 2018-10-15 | 2019-02-15 | 北京世纪元亨动物防疫技术有限公司 | 一种猪流行性腹泻病毒的纯化方法 |
| WO2020106358A1 (en) | 2018-11-20 | 2020-05-28 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
| CN109627297B (zh) * | 2018-12-29 | 2022-06-14 | 复旦大学 | 来自寨卡病毒e蛋白的中和表位及其应用 |
| CN114206103A (zh) * | 2019-01-22 | 2022-03-18 | 蓝鸟生物公司 | 用于制造病毒载体的方法和系统 |
| CN113939311A (zh) * | 2019-05-08 | 2022-01-14 | 武田疫苗股份有限公司 | 灭活病毒组合物和寨卡疫苗制剂 |
| EP4010016A1 (en) | 2019-08-09 | 2022-06-15 | Valneva SE | Single shot chikungunya virus vaccine |
| BR112022002082A2 (pt) | 2019-08-09 | 2022-04-12 | Valneva Se | Formulações de vacina contra o chikungunya |
| EP4028511A1 (en) | 2019-09-09 | 2022-07-20 | Valneva Austria GmbH | Inactivation process for viruses |
| KR102243295B1 (ko) * | 2019-11-15 | 2021-04-23 | 강원대학교산학협력단 | 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물 |
| KR102365464B1 (ko) * | 2019-12-24 | 2022-02-22 | 강원대학교산학협력단 | 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법 |
| WO2021158815A1 (en) * | 2020-02-05 | 2021-08-12 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
| WO2021176434A1 (en) | 2020-03-01 | 2021-09-10 | Valneva Austria Gmbh | Cpg-adjuvanted sars-cov-2 virus vaccine |
| EP4114463A4 (en) | 2020-03-01 | 2023-09-06 | Dynavax Technologies Corporation | CORONAVIRUS VACCINES INCLUDING A TLR9 AGONIST |
| EP3895729A1 (en) | 2020-03-01 | 2021-10-20 | Valneva Austria GmbH | Cpg-adjuvanted sars-cov-2 virus vaccine |
| US20240189412A1 (en) * | 2020-03-03 | 2024-06-13 | Mayo Foundation For Medical Education And Research | Zika Virus Polypeptides |
| UY39159A (es) | 2020-04-06 | 2021-10-29 | Valneva Austria Gmbh | VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2 |
| WO2021236225A1 (en) | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| EP4153222A1 (en) | 2020-05-20 | 2023-03-29 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| US20230204567A1 (en) | 2020-05-20 | 2023-06-29 | Takeda Vaccines, Inc. | Method for determining the potency of antigens |
| WO2023148256A1 (en) | 2022-02-02 | 2023-08-10 | Valneva Austria Gmbh | Inactivated sars-cov-2 virus vaccine |
| EP4476329A1 (en) * | 2022-02-09 | 2024-12-18 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| WO2025099278A2 (en) * | 2023-11-08 | 2025-05-15 | Valneva Austria Gmbh | Immunogenic zika virus compositions and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US86061A (en) * | 1869-01-19 | Improved horse-power | ||
| NZ503522A (en) * | 1997-08-28 | 2001-06-29 | Us Army | Attenuated Japanese encephalitis virus adapted to vero cell and a Japanese encephalitis vaccine |
| WO2000014245A1 (en) * | 1998-09-02 | 2000-03-16 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Dengue viruses that are replication defective in mosquitos for use as vaccines |
| DE60135983D1 (de) | 2000-05-31 | 2008-11-13 | Novartis Vaccines & Diagnostic | Verfahren zur reinigung von alphaviralen replikon partikeln |
| WO2002074963A1 (en) * | 2001-03-16 | 2002-09-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt | Dengue viruses that are replication defective in mosquitos for use as vaccines |
| WO2002089840A1 (en) * | 2001-05-10 | 2002-11-14 | The Regents Of The University Of California | Recombinant bicistronic flaviviruses and methods of use thereof |
| DE602004029657D1 (de) | 2003-03-24 | 2010-12-02 | Intercell Ag | Verbesserte impfstoffe |
| CN101516395B (zh) * | 2006-09-01 | 2014-03-26 | 伯哈拉特生物技术国际有限公司 | 抗屈曲病毒感染的疫苗 |
| WO2009048633A2 (en) | 2007-10-11 | 2009-04-16 | The Board Of Regents Of The University Of Texas System | Chimeric chikungunya virus and uses thereof |
| EP2288359B1 (en) * | 2008-04-21 | 2019-10-02 | Tissue Regeneration Therapeutics Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
| CN102317308A (zh) * | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| WO2010085358A2 (en) * | 2009-01-23 | 2010-07-29 | The Board Of Regents Of The University Of Texas System | Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
| WO2011101465A1 (en) * | 2010-02-19 | 2011-08-25 | Intercell Ag | Ic31 nanoparticles |
| DK3785730T3 (da) | 2011-12-06 | 2024-05-06 | Valneva Austria Gmbh | Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner |
| US9895437B2 (en) * | 2012-04-18 | 2018-02-20 | Valneva Austria Gmbh | Aluminum compounds for use in therapeutics and vaccines |
| WO2016145149A1 (en) | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
| MY187459A (en) | 2015-07-16 | 2021-09-23 | Bharat Biotech Int Ltd | Vaccine compositions |
| HUE061679T2 (hu) | 2015-12-23 | 2023-08-28 | Valneva Austria Gmbh | Zika vírus vakcina |
| CN105749268B (zh) | 2016-04-11 | 2020-09-11 | 北京科兴中维生物技术有限公司 | 一种灭活的寨卡病毒疫苗 |
| CR20200082A (es) | 2017-09-21 | 2020-05-17 | Valneva Se | Virus chikungunya inmunogénico |
-
2016
- 2016-12-23 HU HUE16828746A patent/HUE061679T2/hu unknown
- 2016-12-23 DK DK16828746.4T patent/DK3393510T5/da active
- 2016-12-23 WO PCT/EP2016/082667 patent/WO2017109228A1/en not_active Ceased
- 2016-12-23 BR BR112018012873-2A patent/BR112018012873A2/pt active Search and Examination
- 2016-12-23 AU AU2016375338A patent/AU2016375338B2/en active Active
- 2016-12-23 EP EP16826740.9A patent/EP3393507B1/en active Active
- 2016-12-23 EP EP16828745.6A patent/EP3393509B1/en active Active
- 2016-12-23 US US15/781,825 patent/US10744194B2/en active Active
- 2016-12-23 CN CN201680074939.XA patent/CN108697785B/zh active Active
- 2016-12-23 WO PCT/EP2016/082666 patent/WO2017109227A1/en not_active Ceased
- 2016-12-23 JP JP2018532747A patent/JP6949027B2/ja active Active
- 2016-12-23 CA CA3009278A patent/CA3009278A1/en active Pending
- 2016-12-23 US US16/060,054 patent/US11331382B2/en active Active
- 2016-12-23 PL PL16828746.4T patent/PL3393510T3/pl unknown
- 2016-12-23 WO PCT/EP2016/082662 patent/WO2017109223A1/en not_active Ceased
- 2016-12-23 MX MX2018007627A patent/MX2018007627A/es unknown
- 2016-12-23 HR HRP20230273TT patent/HRP20230273T1/hr unknown
- 2016-12-23 US US16/062,245 patent/US10537630B2/en active Active
- 2016-12-23 LT LTEPPCT/EP2016/082664T patent/LT3393510T/lt unknown
- 2016-12-23 SI SI201631676T patent/SI3393510T1/sl unknown
- 2016-12-23 ES ES16828745T patent/ES2973267T3/es active Active
- 2016-12-23 EP EP24159155.1A patent/EP4393938A3/en active Pending
- 2016-12-23 EP EP16826739.1A patent/EP3393506B1/en active Active
- 2016-12-23 SG SG11201805120YA patent/SG11201805120YA/en unknown
- 2016-12-23 CN CN202210678575.3A patent/CN115381934A/zh active Pending
- 2016-12-23 WO PCT/EP2016/082664 patent/WO2017109225A1/en not_active Ceased
- 2016-12-23 EP EP23175136.3A patent/EP4253403A3/en active Pending
- 2016-12-23 KR KR1020187017319A patent/KR20180097558A/ko active Pending
- 2016-12-23 ES ES16826741T patent/ES2950887T3/es active Active
- 2016-12-23 ES ES16826739T patent/ES2976311T3/es active Active
- 2016-12-23 FI FIEP16828746.4T patent/FI3393510T3/fi active
- 2016-12-23 EP EP23152481.0A patent/EP4218807A3/en active Pending
- 2016-12-23 WO PCT/EP2016/082668 patent/WO2017109229A1/en not_active Ceased
- 2016-12-23 US US16/063,007 patent/US10639365B2/en active Active
- 2016-12-23 EP EP16826741.7A patent/EP3393508B9/en active Active
- 2016-12-23 US US15/781,959 patent/US10660950B2/en active Active
- 2016-12-23 WO PCT/EP2016/082663 patent/WO2017109224A1/en not_active Ceased
- 2016-12-23 ES ES16828746T patent/ES2941967T3/es active Active
- 2016-12-23 EP EP23219512.3A patent/EP4357355A3/en active Pending
- 2016-12-23 EP EP16828746.4A patent/EP3393510B1/en active Active
-
2019
- 2019-12-04 US US16/702,764 patent/US11207397B2/en active Active
-
2020
- 2020-03-10 US US16/813,862 patent/US11219681B2/en active Active
- 2020-04-06 US US16/840,760 patent/US11406700B2/en active Active
- 2020-07-13 US US16/927,086 patent/US11524064B2/en active Active
-
2021
- 2021-12-13 US US17/548,721 patent/US12005111B2/en active Active
-
2022
- 2022-07-06 US US17/811,059 patent/US12214033B2/en active Active
-
2023
- 2023-03-06 US US18/178,638 patent/US11951163B2/en active Active
- 2023-06-14 US US18/334,497 patent/US12102673B2/en active Active
-
2024
- 2024-08-09 US US18/799,291 patent/US20250018023A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230273T1 (hr) | Cjepivo protiv zika virusa | |
| Mountcastle et al. | Proteins and glycoproteins of paramyxoviruses: a comparison of simian virus 5, Newcastle disease virus, and Sendai virus | |
| JP2019504030A5 (enExample) | ||
| Simons et al. | Uukuniemi virus S RNA segment: ambisense coding strategy, packaging of complementary strands into virions, and homology to members of the genus Phlebovirus | |
| JP2024161055A (ja) | 安定化されたｎａを有する組換えインフルエンザウイルス | |
| US9750800B2 (en) | Method for purifying the rabies virus | |
| Blok et al. | Variation in the membrane-insertion and" stalk" sequences in eight subtypes of influenza type A virus neuraminidase | |
| RU2011153597A (ru) | Материалы и методы, используемые для лечения респираторных заболеваний у собак | |
| Thompson et al. | Localization of functional sites on the hemagglutinin-neuraminidase glycoprotein of Sendai virus by sequence analysis of antigenic and temperature-sensitive mutants | |
| RU2013120979A (ru) | Северо-американский вирус репродуктивно-респираторного синдрома свиней (prrs) и его применения | |
| Quan et al. | Moussa virus: a new member of the Rhabdoviridae family isolated from Culex decens mosquitoes in Cote d’Ivoire | |
| Mohammed et al. | First report of Papaya ringspot virus in pumpkin in Sudan | |
| Halpin et al. | Recent progress in henipavirus research | |
| St-Laurent et al. | Genetic and amino acid analysis of the GL protein of Canadian, American and European equine arteritis virus isolates | |
| Tischler et al. | Complete sequence of the genome of the human isolate of Andes virus CHI-7913: comparative sequence and protein structure analysis | |
| Storey et al. | Nucleotide Sequence of the Coding and Flanking Regions of the Human Parainfluenza Virus 3 Hemagglutinin–Neuraminidase Gene: Comparison with Other Paramyxoviruses | |
| Esmaelizad et al. | Identification of 23 specific nucleotide patterns in the HN gene of Newcastle disease viruses isolated from Iran | |
| WO2022008700A1 (en) | Process for producing a purified rhabdovirus from cell culture | |
| Romine et al. | COVID-19 Vaccine Manufacturing Processes: Making the Molecules to Solve the Pandemic | |
| CN104513813A (zh) | 一种带状疱疹病毒的制备方法 | |
| HK1261562B (en) | Virus purification | |
| Baričević et al. | Determination of the coding and noncoding nucleotide sequences of original Edmonston-Zagreb master seed and current working seed | |
| Chen et al. | Preparation of rabbit antibody against SLC38A3 and its subcellular localization in A549 | |
| Hock | Structural Analyses of Borna Disease Virus Nucleoprotein-Phosphoprotein and Nucleoprotein-RNA Interactions |